These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16277272)

  • 1. [Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine].
    Ijiri S
    Nihon Rinsho; 2005 Nov; 63(11):2059-67. PubMed ID: 16277272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 3. [Differences among bisfosfonates--specificity of risedronate (Actonel)].
    Giljević Z
    Reumatizam; 2008; 55(2):78-80. PubMed ID: 19024283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence.
    Ringe JD; van der Geest SA; Möller G
    Drugs Aging; 2006; 23(7):569-78. PubMed ID: 16930085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis in older people: a tale of two studies (and three treatments).
    Troen BR
    J Am Geriatr Soc; 2006 May; 54(5):853-5. PubMed ID: 16696755
    [No Abstract]   [Full Text] [Related]  

  • 6. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
    Gold DT; Trinh H; Safi W
    Curr Med Res Opin; 2009 Aug; 25(8):1831-9. PubMed ID: 19530982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis].
    Suzuki Y
    Clin Calcium; 2006 Nov; 16(11):1834-42. PubMed ID: 17079850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When do bisphosphonates make the most sense?
    Winzenberg T; Jones G
    J Fam Pract; 2011 Jan; 60(1):18-28. PubMed ID: 21209974
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucocorticoid-induced osteoporosis: hope on the HORIZON.
    Gennari L; Bilezikian JP
    Lancet; 2009 Apr; 373(9671):1225-6. PubMed ID: 19362657
    [No Abstract]   [Full Text] [Related]  

  • 10. How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.
    Ferko NC; Borisova N; Airia P; Grima DT; Thompson MF
    Manag Care; 2012 Nov; 21(11):44-52. PubMed ID: 23236717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
    Kishimoto H
    Clin Calcium; 2008 Oct; 18(10):1417-26. PubMed ID: 18830038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and compliance with risedronate in clinical practice.
    Hamilton B; McCoy K; Taggart H
    Osteoporos Int; 2003 May; 14(3):259-62. PubMed ID: 12730745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S; Jeglitsch M; McCloskey E
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
    Giljević Z; Vlak T
    Reumatizam; 2006; 53(2):66-71. PubMed ID: 17580558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risedronate for treatment of osteoporosis].
    Hagino H
    Nihon Rinsho; 2009 May; 67(5):948-53. PubMed ID: 19432115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
    Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
    Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W; Emkey R; Civitelli R
    Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT; Safi W; Trinh H
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fracture protection in osteoporosis with risedronate.
    Boonen S; Vanderschueren D
    Hosp Med; 2004 Sep; 65(9):535-40. PubMed ID: 15449490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.